Phentermine Plus Topiramate for Weight Reduction

Kartal, Ömer; Kartal, Ayşe Tuğba

doi:10.1177/0009922814566935

Cited by 2 publications

(8 citation statements)

References 5 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This combined effect is attributed to the synergy between noradrenergic agonist action of phentermine and influence of topiramate on GABA‐A receptors, leading to a more potent appetite suppression than when either drug is taken singly 4 . Common reported side effects were paresthesia, dizziness, dysgeusia, insomnia, constipation, palpitations, tachycardia, and dry mouth 42 . These adverse events, predominantly mild to moderate in intensity, are often dose‐related and tend to arise during the medication titration phase 4,42 .…”

Section: Discussionmentioning

confidence: 99%

“…Common reported side effects were paresthesia, dizziness, dysgeusia, insomnia, constipation, palpitations, tachycardia, and dry mouth 42 . These adverse events, predominantly mild to moderate in intensity, are often dose‐related and tend to arise during the medication titration phase 4,42 . Severe adverse events are rare, mainly identified as cardiac‐related disorders 4,42 .…”

Section: Discussionmentioning

confidence: 99%

“…These adverse events, predominantly mild to moderate in intensity, are often dose‐related and tend to arise during the medication titration phase 4,42 . Severe adverse events are rare, mainly identified as cardiac‐related disorders 4,42 . However, given the high heterogeneity of obesity, having a variety of pharmacotherapy options allows physicians to adopt a more personalized approach to treatment.…”

Section: Discussionmentioning

confidence: 99%

“…42 These adverse events, predominantly mild to moderate in intensity, are often dose-related and tend to arise during the medication titration phase. 4,42 Severe adverse events are rare, mainly identified as cardiac-related disorders. not observe any substantial impact of the therapy on QOL.…”

Section: Discussionmentioning

confidence: 99%

“…4,42 However, given the high heterogeneity of obesity, having a variety of F I G U R E 6 Forest plots of incretin-based therapies versus control group to assess adverse effects risk of (A) nausea, (B) vomiting, (C) diarrhea, and (D) abdominal pain.pharmacotherapy options allows physicians to adopt a more personalized approach to treatment. Beyond the efficacy and safety discussed above, several topics warrant attention.…”

mentioning

confidence: 99%

See 4 more Smart Citations

The effects of incretin‐based therapies on weight reduction and metabolic parameters in children with obesity: A systematic review and meta‐analysis

Wang,

Kang,

et al. 2024

Obesity Reviews

View full text Add to dashboard Cite

SummaryBackgroundGrowing evidence indicates that incretin‐based therapies (IBTs), glucagon‐like peptide‐1 receptor agonists (GLP‐1 RAs), and dipeptidyl peptidase‐4 inhibitors (DPP4is) are effective and safe for treating pediatric obesity patients with or without type 2 diabetes. Therefore, we aimed to perform a systematic review and meta‐analysis for updating current evidence.MethodsWe searched the PubMed, the Cochrane Library, and the EMBASE database for articles published until September 15, 2023, and limited to randomized control trials. The primary outcomes were changed from baseline in weight metrics and the cardiometabolic profile. A random effects model will be used, as high heterogeneity is expected. All analyses were performed using STATA 17.0.ResultsFifteen trials with a total number of 1286 participants were included in our meta‐analysis. Overall, the mean difference in weight change between the IBTs group and the control group was −2.89 kg (95% confidence interval, −5.12 to −0.65, p = 0.011). Additionally, IBTs significantly reduced the HbA1c level and fasting plasma glucose by 0.37% and 6.99 mg/dl, compared with control groups. IBTs showed a little increased risk of GI side effects and hypoglycemia events, but none of the severe hypoglycemia events were occurred in IBTs group.ConclusionsOur study results have proved that GLP‐1 RAs are safe, acceptable, and effective in weight reduction and sugar control for children with obesity. In addition, DPP‐4is seems to have no effect on glycemic control and weight loss in childhood obesity. Further research is needed to confirm these findings, especially in younger children.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

mentioning

confidence: 99%

See 3 more Smart Citations

The effects of incretin‐based therapies on weight reduction and metabolic parameters in children with obesity: A systematic review and meta‐analysis

Wang,

Kang,

et al. 2024

Obesity Reviews

View full text Add to dashboard Cite

show abstract

A Narrative Review: Phentermine and Topiramate for the Treatment of Pediatric Obesity

Kim,

Nguyen,

Babaei

et al. 2023

AHMT

View full text Add to dashboard Cite

The prevalence of pediatric obesity has increased exponentially over the past four decades. The American Academy of Pediatrics recently released updated clinical practice guidelines highlighting the importance of identifying pediatric obesity as a chronic disease. The guidelines support consideration of concurrent treatment with intensive lifestyle interventions, obesity pharmacotherapy, and bariatric surgery. The dramatic rise in pediatric obesity has spurred interest in utilizing obesity pharmacotherapy to support sustained weight reduction in pediatric cohorts, in the hopes of preventing the emergence of later-appearing, significant co-morbidities. Despite the enormous demand, the obstacles posed by performance of needed clinical trials in the pediatric population markedly limits available pharmacotherapy for the treatment of obesity in pediatrics. Currently, there are five medications approved by the Food and Drug Administration for use in youth with obesity. In 2022, the phentermine/topiramate (PHEN/TPM), once-daily, controlled-release, combination product received FDA approval, for the indication of chronic weight management, in youth with obesity, ages 12 years and older. The objectives of this narrative review are to: (1) Review the mechanism of action of phentermine and topiramate, (2) Summarize the safety and efficacy data of topiramate and phentermine use as both monotherapies and in combination, and (3) Discuss clinical practice guidelines and clinical implications, for the use of these agents in youths with obesity.

show abstract

Phentermine Plus Topiramate for Weight Reduction

Cited by 2 publications

References 5 publications

The effects of incretin‐based therapies on weight reduction and metabolic parameters in children with obesity: A systematic review and meta‐analysis

The effects of incretin‐based therapies on weight reduction and metabolic parameters in children with obesity: A systematic review and meta‐analysis

A Narrative Review: Phentermine and Topiramate for the Treatment of Pediatric Obesity

Contact Info

Product

Resources

About